All In Biotech

Drug Trial Radar · NCT03627130

The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy

Effect of Inorganic Nitrate on Contrast-induced Nephropathy in Patients Undergoing Coronary Angiography/Percutaneous Coronary Intervention for Acute Coronary Syndrome (ACS): A Randomised Single-centre, Double-blind Placebo-controlled Trial

Last checked: Nov 19, 2026Latest source record: Dec 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 640 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

640

Actual

Start

Nov 29, 2018

Primary completion

May 30, 2022

Study completion May 30, 2022

Sponsor

Lead sponsor
Barts & The London NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 13, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Contrast-induced nephropathy (CIN), an acute kidney injury resulting from the administration of intravascular iodinated contrast media, is an important cause of morbidity/mortality following coronary angiographic procedures in high-risk patients. Despite preventative measures intended to mitigate the risk of CIN, there remains a need for an effective intervention. Dietary inorganic nitrate therapy, which through its chemical reduction in the body delivers nitric oxide has shown promise in attenuating CIN, but its effectiveness in preserving long-term renal function is unknown.

Conditions

  • Contrast-induced Nephropathy
  • Acute Kidney Injury
  • Acute Coronary Syndrome

Interventions

  • Potassium NitrateDrug

    Potassium nitrate capsules (KNO3: 12 mmol giving 744 mg of nitrate) for 5 days

  • Potassium ChlorideDrug

    Potassium Chloride capsules for 5 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Contrast Induced NephropathyTime frame: 48-72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Barts Heart Centre

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.